

BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES

ALEXANDER V. LYUBIMOV¹ AND IHOR BEKERSKY²

¹*University of Illinois at Chicago, Chicago, Illinois*

²*Consultant, Antioch, Illinois*

Contents

- 1 Introduction
 - 1.1 Rationale for Bioavailability/Bioequivalence (BA/BE) Studies
 - 1.2 Need and Aim of BA/BE Studies
 - 1.3 Role of BA/BE Studies in Drug Development and Nonclinical Studies
 - 1.4 Regulatory Considerations and Guidelines
 - 1.5 Importance of Safety Margins
 - 1.6 Definitions
- 2 IND-Targeted Nonclinical Development
 - 2.1 Objective
 - 2.2 Species in IND-Targeted Toxicology Studies
 - 2.3 Key Elements of IND-Target Development
 - 2.4 Use of Animal Models for the Selection of Dosage Forms for Nonclinical Toxicology Studies
 - 2.5 Species Differences in Bioavailability
- 3 NDA-Targeted Nonclinical Development
 - 3.1 Toxicokinetics in Chronic Toxicity Studies
 - 3.2 Use of Animals to Evaluate the BA/BE of Clinical Dosage Forms
 - 3.3 Role and Impact of Nonclinical Studies on Clinical Development: Animal to Humans
- 4 Conclusions
- References